## Protocol Section
### Identification Module
**NCT ID:** NCT06424262

**Acronym:** DETECT

**Brief Title:** Performance and Hearing-related Outcomes in Adults Implanted With the CI622D Dexamethasone-eluting Cochlear Implant Compared to Those Implanted With a Standard Cochlear Implant (CI622)

**Official Title:** A Pivotal, Prospective, Multi-centre, Randomised Controlled, Blinded Investigation Evaluating the Efficacy of a Dexamethasone Eluting Slim Straight Electrode (CI622D) in the Reduction of Impedance as Compared to a Standard Slim Straight Electrode (CI622) in a Newly Implanted Adult Population With Post-linguistic, Bilateral, Moderately Severe to Profound Sensorineural Hearing Loss.

#### Organization Study ID Info
**ID:** CLTD5815
#### Organization
**Class:** INDUSTRY
**Full Name:** Cochlear
### Status Module
#### Completion Date
**Date:** 2026-05

**Type:** ESTIMATED

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2024-05-22

**Type:** ACTUAL

**Last Update Submit Date:** 2024-05-16

**Overall Status:** NOT_YET_RECRUITING

#### Primary Completion Date
**Date:** 2025-12

**Type:** ESTIMATED

#### Start Date
**Date:** 2024-06

**Type:** ESTIMATED

**Status Verified Date:** 2024-05

#### Study First Post Date
**Date:** 2024-05-22
**Type:** ACTUAL
**Study First Submit Date:** 2024-05-16
**Study First Submit QC Date:** 2024-05-16
### Sponsor Collaborators Module

#### Collaborators

**Class:** UNKNOWN

**Name:** QbD Clinical

**Class:** INDUSTRY

**Name:** Avania

#### Lead Sponsor

**Class:** INDUSTRY

**Name:** Cochlear

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** False

**Oversight Has DMC:** False

### Description Module

**Brief Summary:** This clinical study will test a newly developed cochlear implant known as CI622D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation, which is common after any surgical procedure. The goal is to learn if there are added benefits in implant performance and hearing outcomes with the dexamethasone-releasing cochlear implant (CI622D) vs. the standard cochlear implant (CI622) without dexamethasone. The study will be conducted in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve. The study participants will undergo a series of tests that include testing their implant and their hearing. They will also complete questionnaires to see how they rate their hearing ability and their overall general health.

### Conditions Module

**Conditions:**

- Hearing Loss, Bilateral Sensorineural

- Hearing Loss, Sensorineural

- Hearing Loss, Bilateral

- Hearing Loss, Cochlear

### Design Module

#### Design Info

**Allocation:** RANDOMIZED

**Intervention Model:** PARALLEL

##### Masking Info

**Masking:** DOUBLE

**Who Masked:**

- PARTICIPANT

- CARE_PROVIDER

**Primary Purpose:** TREATMENT

#### Enrollment Info

**Count:** 48

**Type:** ESTIMATED

**Phases:**

- NA

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Investigational Medical Device (IMD)

**Intervention Names:**

- Device: CI622D

**Label:** CI622D

**Type:** EXPERIMENTAL

#### Arm Group 2

**Description:** An approved medical device

**Intervention Names:**

- Device: CI622

**Label:** CI622

**Type:** ACTIVE_COMPARATOR

### Interventions

#### Intervention 1

**Arm Group Labels:**

- CI622D

**Description:** A dexamethasone-eluting Slim Straight electrode

**Name:** CI622D

**Type:** DEVICE

#### Intervention 2

**Arm Group Labels:**

- CI622

**Description:** A standard Slim Straight electrode

**Name:** CI622

**Type:** DEVICE

### Outcomes Module

#### Primary Outcomes

**Description:** The impedance will be measured across the active electrodes of the implant for each participant.

**Measure:** Mean difference in the monopolar 1+2 (MP1+2) impedance between CI622D (Investigational Medical Device) and CI622 (control device) at 3 months post-activation

**Time Frame:** 3 months post-activation

#### Secondary Outcomes

**Description:** Adverse events will be recorded as overall, by severity, by relatedness to device or procedure, or by seriousness. Device deficiency will be recorded as overall and by type.

**Measure:** Proportion of participants who experience an adverse event and the proportion of participants who experience a device deficiency with CI622D and CI622

**Time Frame:** Throughout study (12 months)

**Description:** Unaided acoustic hearing thresholds will be measured pre-operatively, at activation, and 3, 6 and 12 months post-activation.

**Measure:** Difference in the mean unaided acoustic hearing thresholds pre-operatively, and from activation to post-activation between CI622D and CI622

**Time Frame:** Pre-operative, 0, 3, 6, 12 months post-activation

**Description:** Word recognition scores will be measured at pre-implantation and 3, 6 and 12 months post-activation.

**Measure:** Mean within-subject change in word recognition score in the preferred unilateral listening mode in quiet from pre-implantation to post-activation with CI622D

**Time Frame:** Pre-implantation, 3, 6, 12 months post-activation

**Description:** Word recognition scores will be measured at pre-implantation and 3, 6 and 12 months post-activation.

**Measure:** Mean change (within-subject) in word recognition score in the preferred bilateral listening mode in quiet from pre-implantation to post-activation with CI622D

**Time Frame:** Pre-implantation, 3, 6, 12 months post-activation

**Description:** Change in word recognition score will be measured from pre-implantation to 3, 6 and 12 months post-activation.

**Measure:** Difference in mean (within-subject) change in word recognition score in the preferred unilateral listening mode in quiet from pre-implantation to post-activation with CI622D compared with CI622

**Time Frame:** Pre-implantation, 3, 6, 12 months post-activation

**Description:** Change in word recognition score will be measured from pre-implantation to 3, 6 and 12 months post-activation.

**Measure:** Difference in mean (within-subject) change in word recognition score in the preferred bilateral listening mode in quiet from pre-implantation to post-activation with CI622D compared with CI622

**Time Frame:** Pre-implantation, 3, 6, 12 months post-activation

**Description:** Change in sentence recognition score (Matrix test + 10 SNR) will be measured from pre-implantation to 3, 6 and 12 months post-activation.

**Measure:** Difference in mean (within-subject) change in sentence recognition score in noise in the preferred unilateral listening mode from pre-implantation to post-implantation with CI622D compared with CI622

**Time Frame:** Pre-implantation, 3, 6, 12 months post-activation

**Description:** Change in sentence recognition score (Matrix test + 10 SNR) will be measured from pre-implantation to 3, 6 and 12 months post-activation.

**Measure:** Difference in mean (within-subject) change in sentence recognition score in noise in the preferred bilateral listening mode from pre-implantation to post-implantation with CI622D compared with CI622

**Time Frame:** Pre-implantation, 3, 6, 12 months post-activation

**Description:** Four-point monopolar and nested bipolar trans-impedances and MP1+2 impedances will be measured intraoperatively, at activation and 3,6,12 months post-activation.

**Measure:** Difference in the mean four-point monopolar and nested bipolar trans-impedances and MP1+2 impedances between CI622D and CI622 measured intraoperatively and from activation to post-activation

**Time Frame:** Intraoperative, 0, 3, 6, 12 months post-activation

**Description:** The estimated sound processor battery life (hours per day) will be measured at activation, 3, 6, and 12 months-post activation.

**Measure:** Difference in the mean estimated sound processor battery life for CI622D compared from activation to post-activation with CI622

**Time Frame:** 0, 3, 6,12 months post-activation

**Description:** Global SSQ12 scores will be measured between pre-implantation to 3, 6 and 12 months post-activation.

**Measure:** Difference in mean within-subject changes in global score on the Speech, Spatial, and Qualities of Hearing Scale (SSQ12) from pre-implantation to post-activation between CI622D and CI622

**Time Frame:** Pre-implantation, 3, 6, 12 months post-activation

**Description:** Global HUI3 scores will be measured between pre-implantation to 3, 6 and 12 months post-activation.

**Measure:** Difference in mean within-subject changes in global Health Utilities Index III (HUI3) from pre-implantation to post-activation between CI622D and CI622

**Time Frame:** Pre-implantation, 3, 6, 12 months post-activation

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

* Aged 18 years or older (at time of consent)
* Clinically established post-linguistic bilateral moderately severe to profound sensorineural hearing loss
* Meets local candidacy criteria for cochlear implantation
* Compromised functional hearing with a hearing aid in the ear to be implanted
* Willing to participate in and comply with all requirements of the protocol, including willingness to be randomised to either arm
* Evidence of pneumococcal vaccination (e.g., Pneumovax) according to local guidelines prior to randomisation
* Candidate is proficient in the language used to assess speech perception performance
* Willing and able to provide written informed consent.

Exclusion Criteria:

* Planned for a partial insertion of the electrode array
* Deafness due to lesions of the acoustic nerve or central auditory pathway, affecting either ear
* Active middle-ear infection, in the ear to be implanted
* Active autoimmune disease, active immunosuppressive therapy, or use of anticoagulants that cannot be discontinued for surgery
* Surgery (including grommets), drainage, presence of an unhealed tympanic membrane, pain, or need for oral or topical antibiotics within 6 months prior to randomisation, in the ear to be implanted
* Previously reported diagnosis of auditory neuropathy, in either ear
* Previously reported diagnosis, in either ear, of Large Vestibular Aqueduct Syndrome (LVAS), Meniere's disease, or cochlear hydrops
* Ossification, otosclerosis, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, as confirmed by imaging, in the ear to be implanted
* Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, temporo-parietal skull fracture or CSF leaks
* History of bacterial meningitis
* Known allergic reaction or contraindication to dexamethasone or corticosteroids
* Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the subject
* Severe, or poorer, sensorineural hearing loss of more than 20 years, as reported by the subject, in the ear to be implanted
* Prior cochlear implantation, in either ear
* Medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted
* Medical or psychological conditions that contraindicate general anaesthesia, surgery or participation in the clinical investigation
* Women who are pregnant or breastfeeding or plan to become pregnant during the investigation
* Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices as determined by the Investigator
* Additional disabilities that may affect the subject's participation or safety during the clinical investigation, as determined by the Investigator
* Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator
* Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as spouse, parent, child, or sibling to the study candidate
* Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation
* Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless the other investigation was/is a Cochlear sponsored investigation and determined by the Investigator or Sponsor to not impact this investigation)
* Subjects recruited at a French site who are not affiliated with social security
* Subjects recruited at a French site who are under legal protection.

**Minimum Age:** 18 Years

**Sex:** ALL

**Standard Ages:**

- ADULT

- OLDER_ADULT

### Contacts Locations Module

#### Central Contacts

**Contact 1:**

**Email:** ccampbellbell@cochlear.com

**Name:** Cherith Campbell-Bell

**Phone:** +6129428 6555

**Role:** CONTACT

**Contact 2:**

**Email:** breusens@cochlear.com

**Name:** Beatrice Reusens

**Phone:** +32485759196

**Role:** CONTACT

#### Locations

**Location 1:**

**City:** Sydney

**Contacts:**

***Contact 1:***

- **Name:** Catherine Birman, MD

- **Role:** CONTACT

***Contact 2:***

- **Name:** Catherine Birman

- **Role:** PRINCIPAL_INVESTIGATOR

**Country:** Australia

**Facility:** Royal Prince Alfred Hospital

**State:** New South Wales

**Location 2:**

**City:** Melbourne E.

**Contacts:**

***Contact 1:***

- **Name:** Stephen O'Leary, MD

- **Role:** CONTACT

***Contact 2:***

- **Name:** Stephen O'Leary

- **Role:** PRINCIPAL_INVESTIGATOR

**Country:** Australia

**Facility:** Royal Victorian Eye and Ear Hospital

**State:** Victoria

**Location 3:**

**City:** Lille

**Contacts:**

***Contact 1:***

- **Name:** Christophe Vincent, MD

- **Role:** CONTACT

***Contact 2:***

- **Name:** Christophe Vincent, MD

- **Role:** PRINCIPAL_INVESTIGATOR

**Country:** France

**Facility:** Centre Hospitalier Universitaire de Lille

**Location 4:**

**City:** Paris

**Contacts:**

***Contact 1:***

- **Name:** Isabelle Mosnier, MD

- **Role:** CONTACT

***Contact 2:***

- **Name:** Isabelle Mosnier

- **Role:** PRINCIPAL_INVESTIGATOR

**Country:** France

**Facility:** Hôpital Universitaire Pitié-Salpêtrière

**Location 5:**

**City:** Toulouse

**Contacts:**

***Contact 1:***

- **Name:** Olivier Deguine, MD

- **Role:** CONTACT

***Contact 2:***

- **Name:** Olivier Deguine

- **Role:** PRINCIPAL_INVESTIGATOR

**Country:** France

**Facility:** Centre Hospitalier Universitaire Toulouse

**Location 6:**

**City:** Freiburg

**Contacts:**

***Contact 1:***

- **Name:** Antje Aschendorff, MD

- **Role:** CONTACT

***Contact 2:***

- **Name:** Antje Aschendorff

- **Role:** PRINCIPAL_INVESTIGATOR

**Country:** Germany

**Facility:** Universitätsklinikum Freiburg

**State:** Freiburg Im Breisgau

**Location 7:**

**City:** Hannover

**Contacts:**

***Contact 1:***

- **Name:** Thomas Lenarz, MD

- **Role:** CONTACT

***Contact 2:***

- **Name:** Thomas Lenarz

- **Role:** PRINCIPAL_INVESTIGATOR

**Country:** Germany

**Facility:** Medizinische Hochschule Hannover

**State:** Niedersachsen

**Location 8:**

**City:** Manchester

**Contacts:**

***Contact 1:***

- **Name:** Emma Stapleton, MD

- **Role:** CONTACT

***Contact 2:***

- **Name:** Emma Stapleton, MD

- **Role:** PRINCIPAL_INVESTIGATOR

**Country:** United Kingdom

**Facility:** Manchester Royal Infirmary

**Location 9:**

**City:** Southampton

**Contacts:**

***Contact 1:***

- **Name:** William Hellier, MD

- **Role:** CONTACT

***Contact 2:***

- **Name:** William Hellier, MD

- **Role:** PRINCIPAL_INVESTIGATOR

**Country:** United Kingdom

**Facility:** University of Southampton

#### Overall Officials

**Official 1:**

**Affiliation:** Universitätsklinikum Freiburg

**Name:** Antje Aschendorff

**Role:** PRINCIPAL_INVESTIGATOR

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000006311

- Term: Hearing Disorders

- ID: D000004427

- Term: Ear Diseases

- ID: D000010038

- Term: Otorhinolaryngologic Diseases

- ID: D000012678

- Term: Sensation Disorders

- ID: D000009461

- Term: Neurologic Manifestations

- ID: D000009422

- Term: Nervous System Diseases

### Condition Browse Module - Browse Branches

- Abbrev: BC09

- Name: Ear, Nose, and Throat Diseases

- Abbrev: BC10

- Name: Nervous System Diseases

- Abbrev: BC23

- Name: Symptoms and General Pathology

- Abbrev: All

- Name: All Conditions

### Condition Browse Module - Browse Leaves

- ID: M24420

- Name: Hearing Loss

- Relevance: HIGH

- As Found: Hearing Loss

- ID: M6840

- Name: Deafness

- Relevance: HIGH

- As Found: Hearing Loss

- ID: M9407

- Name: Hearing Loss, Sensorineural

- Relevance: HIGH

- As Found: Hearing Loss, Sensorineural

- ID: M9401

- Name: Hearing Loss, Bilateral

- Relevance: HIGH

- As Found: Hearing Loss, Bilateral

- ID: M9400

- Name: Hearing Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M7601

- Name: Ear Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M12961

- Name: Otorhinolaryngologic Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M15490

- Name: Sensation Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M12404

- Name: Neurologic Manifestations

- Relevance: LOW

- As Found: Unknown

### Condition Browse Module - Meshes

- ID: D000034381

- Term: Hearing Loss

- ID: D000003638

- Term: Deafness

- ID: D000006319

- Term: Hearing Loss, Sensorineural

- ID: D000006312

- Term: Hearing Loss, Bilateral

### Intervention Browse Module - Browse Branches

- Abbrev: Infl

- Name: Anti-Inflammatory Agents

- Abbrev: ANeo

- Name: Antineoplastic Agents

- Abbrev: AnEm

- Name: Antiemetics

- Abbrev: Gast

- Name: Gastrointestinal Agents

- Abbrev: All

- Name: All Drugs and Chemicals

### Intervention Browse Module - Browse Leaves

- ID: M7102

- Name: Dexamethasone

- Relevance: LOW

- As Found: Unknown

- ID: M235549

- Name: Dexamethasone acetate

- Relevance: LOW

- As Found: Unknown

### Misc Info Module

- Version Holder: 2024-05-31
